Drug‐Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism
- 6 October 2015
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 99 (4) , 390-400
Abstract
Abnormalities of glucose metabolism and glucose tolerance, either because of a reduction in tissue sensitivity to insulin (e.g., in liver, skeletal muscle, and adipose tissues) and/or a reduction in pancreatic insulin secretion, are associated with a number of unwanted health outcomes. Even small increases in circulating glucose levels (often described as dysglycemia or prediabetes) may confer an increased risk of cardiovascular (CV) disease and progression to overt type 2 diabetes. A number of drug therapies, many of them used long term in chronic disease management, have adverse effects on glucose metabolism, diabetes risk, and glycemic control among patients with preexisting diabetes. In this study, we review the evidence, underlying mechanisms, and the clinical significance of drug‐related adverse effects on glucose metabolism.Keywords
This publication has 72 references indexed in Scilit:
- Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databasesBMJ, 2014
- Comparative Tolerability and Harms of Individual StatinsCirculation: Cardiovascular Quality and Outcomes, 2013
- Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes MellitusThe American Journal of Cardiology, 2013
- Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women's Health InitiativeArchives of internal medicine (1960), 2012
- Predictors of New-Onset Diabetes in Patients Treated With AtorvastatinJACC, 2011
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Rosuvastatin in Older Patients with Systolic Heart FailureNew England Journal of Medicine, 2007
- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialThe Lancet, 2002
- Pravastatin and the Development of Diabetes MellitusCirculation, 2001